Show Summary Details
Page of

Developments in the treatment of hepatitis C virus infection 

Developments in the treatment of hepatitis C virus infection
Developments in the treatment of hepatitis C virus infection

Tomas Doyle

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 24 January 2022

The burden of HCV-related diseases, in terms of mortality and cost, remains considerable and HCV remains a potential cause of morbidity, mortality, and need for liver transplantation. For many years, patients with chronic HCV have been promised that new, more effective drugs are ‘just around the corner’. Now, advances in drug discovery mean that there is a pipeline of candidate drugs in development and many at the stage of clinical testing with encouraging results. This chapter describes a case of a patient who has relapsed on traditional ribavirin and interferon therapy and is successfully treated with a new regimen containing a directly acting antiviral (DAA). DAAs are discussed with particular attention to prognostic indicators and side-effect profiles.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.